iRhythm TechnologiesIRTC
IRTC
About: iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Employees: 2,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
22% more capital invested
Capital invested by funds: $2.54B [Q3] → $3.09B (+$551M) [Q4]
0.03% less ownership
Funds ownership: 109.68% [Q3] → 109.66% (-0.03%) [Q4]
6% less funds holding
Funds holding: 238 [Q3] → 223 (-15) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 81
24% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 51
56% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $25.8M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$124
12%
downside
Avg. target
$140
0%
upside
High target
$151
8%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Canaccord Genuity William Plovanic 43% 1-year accuracy 20 / 47 met price target | 1%downside $139 | Buy Maintained | 2 May 2025 |
Wells Fargo Nathan Treybeck 25% 1-year accuracy 1 / 4 met price target | 7%downside $130 | Overweight Upgraded | 2 May 2025 |
Baird Mike Polark 54% 1-year accuracy 7 / 13 met price target | 7%upside $150 | Outperform Maintained | 2 May 2025 |
Needham David Saxon 59% 1-year accuracy 37 / 63 met price target | 8%upside $151 | Buy Maintained | 2 May 2025 |
Goldman Sachs David Roman 41% 1-year accuracy 9 / 22 met price target | 12%downside $124 | Neutral Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 8 articles about IRTC published over the past 30 days
Positive
Benzinga
1 week ago
Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts
iRhythm Technologies Inc IRTC on Thursday reported first quarter 2025 revenue of $158.7 million, up 20.3% year over year, beating the consensus of $153.38 million.
Neutral
Seeking Alpha
1 week ago
iRhythm Technologies, Inc. (IRTC) Q1 2025 Earnings Call Transcript
iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, IR Quentin Blackford - President & CEO Daniel Wilson - CFO Conference Call Participants Allen Gong - JPMorgan Kallum Titchmarsh - Morgan Stanley Macauley Kilbane - William Blair Nathan Treybeck - Wells Fargo David Rescott - Baird David Saxon - Needham & Company Suraj Kalia - Oppenheimer Jon Young - Canaccord Genuity Sam Eiber - BTIG Richard Newitter - Truist Operator Good afternoon. Thank you for attending the iRhythm Technologies, Inc. First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
1 week ago
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
IRhythm Technologies (IRTC) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to loss of $1.47 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection
iRhythm Zio ® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio ® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to Japan Launch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alongside an aging population 1-3 SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio® long-term continuous ECG monitoring (LTCM) system, commercially introduced in this market as the Zio® ECG Recording and Analysis System. The system provides up to 14 days of continuous, uninterrupted ECG monitoring and leverages a deep-learned artificial intelligence (AI) algorithm approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) – and represents a significant advancement over other ambulatory cardiac monitoring options in Japan, including commonly used wired Holter monitors, which capture only 24 to 48 hours of data and other patch-based services that monitor only up to 7 days.
Neutral
GlobeNewsWire
2 weeks ago
iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference
SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2025 Health Care Conference.
Neutral
GlobeNewsWire
2 weeks ago
iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring
Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products.
Neutral
GlobeNewsWire
3 weeks ago
iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025
SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m.
Neutral
GlobeNewsWire
4 weeks ago
iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability
SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its 2024 Corporate Sustainability Report , highlighting the company's efforts to build a sustainable and inclusive future.
Neutral
GlobeNewsWire
1 month ago
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm's Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with Holter devices, fails to detect a significant proportion of actionable arrhythmias—even in patients reporting “daily symptoms”—and that Symptom–Rhythm Correlation (SRC) is notably low for most arrhythmias, underscoring that selection of monitoring duration based on the frequency of symptoms alone can lead to undetected (missed) actionable1 arrhythmias.
Positive
Zacks Investment Research
1 month ago
iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know
iRhythm Technologies (IRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™